Search

everythinglearnresearchcommunity

for

Search:↓

More research is needed on alopecia areata treatments and its psychological effects.

The health of the gut may be important in developing new ways to prevent, diagnose, and treat alopecia areata.

Alopecia areata severely impacts quality of life, causing anxiety, depression, and work impairment.

Further research is needed to understand how the microbiome affects hair loss in Alopecia Areata.

Trichoscopy is a useful tool for diagnosing and managing hair and scalp conditions, often better than traditional methods.

Erdr1 could be a new marker for diagnosing hair loss.

Alopecia Areata is an autoimmune condition causing hair loss, influenced by genetics, environment, and possibly improved by anti-MIF therapy, with many patients experiencing regrowth within a year.

A woman with Kallman's syndrome also developed alopecia universalis, a condition not previously linked to Kallman's.

Proper scalp care can improve hair health and delay ageing signs.

A machine learning model can predict alopecia areata early using specific gene markers.

PPARα agonists may help treat alopecia areata by reducing inflammation.

The EQ-5D-5L tool may not accurately measure the impact of alopecia areata on patients' lives.

Most patients with alopecia areata in Syria are young adult males, often with patchy scalp hair loss.

Traditional treatment for pediatric alopecia areata is most effective and should be first choice.

Certain genetic variants linked to immune response increase the risk of alopecia areata in Taiwanese people.

Corticosteroids are the most common treatment for alopecia areata, but many patients need better options.

Higher antigliadin antibodies are linked to more severe alopecia areata, suggesting screening for celiac disease in these patients.

The Polish Society of Dermatology recommends treatments for alopecia areata that vary by severity, including topical and systemic medications, with long-term maintenance important for management.

Alopecia Areata greatly affects the quality of life and mental health of Canadian patients and their caregivers.

Azathioprine may help treat severe alopecia areata, but more research is needed.

Melanocyte-associated antigens may play a key role in alopecia areata and could be targets for new treatments.

Some cosmetic procedures show promise for treating hair loss, but more research is needed to confirm their safety and effectiveness.

People with alopecia areata have higher levels of osteopontin, which might be important in the disease's development, but this doesn't relate to how severe the disease is.

More severe alopecia areata can lower quality of life.

Alopecia areata is increasing globally, with disparities needing better prevention and support.

Nanotechnology shows promise in improving hair loss treatments by enhancing drug delivery and reducing side effects.

Baseline severity and relapse history affect alopecia areata treatment and recurrence.

The SAALIQ is a reliable tool for measuring the impact of alopecia areata on Spanish-speaking patients' quality of life.

Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.

Gut microbiota changes might play a role in alopecia areata, and microbiome-targeted treatments show promise.